{"id":"placebo-weeks-24-48","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action.","oneSentence":"This drug has no known mechanism of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:48.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04669158","phase":"PHASE1, PHASE2","title":"Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-07-30","conditions":"Non Alcoholic Steatohepatitis, Fibrosis","enrollment":53},{"nctId":"NCT06196879","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)","status":"COMPLETED","sponsor":"Upstream Bio Inc.","startDate":"2024-02-27","conditions":"Severe Asthma","enrollment":479},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06732245","phase":"PHASE2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-08-15","conditions":"Obesity and Overweight","enrollment":224},{"nctId":"NCT04378075","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy","status":"TERMINATED","sponsor":"PTC Therapeutics","startDate":"2020-09-28","conditions":"Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease","enrollment":68},{"nctId":"NCT07486934","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1","status":"NOT_YET_RECRUITING","sponsor":"Dyne Therapeutics","startDate":"2026-04","conditions":"Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy","enrollment":150},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT07469800","phase":"PHASE3","title":"Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-04-01","conditions":"Overweight, Obesity, Hypertensive","enrollment":336},{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT04192136","phase":"NA","title":"NAD+ and Exercise in FA","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-09-03","conditions":"Friedreich Ataxia 1","enrollment":75},{"nctId":"NCT07103746","phase":"PHASE2","title":"Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-26","conditions":"Autoimmune Disorders","enrollment":30},{"nctId":"NCT07459452","phase":"PHASE2","title":"Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-04","conditions":"Perennial Allergic Rhinitis","enrollment":135},{"nctId":"NCT05767034","phase":"PHASE3","title":"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-22","conditions":"Polymyalgia Rheumatica","enrollment":381},{"nctId":"NCT07447102","phase":"PHASE2","title":"Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Dragonboat Biopharmaceutical Company Limited","startDate":"2026-04-01","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":96},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT06892288","phase":"PHASE2, PHASE3","title":"A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glycomine, Inc.","startDate":"2025-07-09","conditions":"Phosphomannomutase 2 Deficiency, PMM2-CDG","enrollment":50},{"nctId":"NCT06047457","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-09-29","conditions":"Episodic Migraine","enrollment":751},{"nctId":"NCT06966479","phase":"PHASE2","title":"A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)","status":"RECRUITING","sponsor":"Upstream Bio Inc.","startDate":"2025-05-21","conditions":"Severe Asthma","enrollment":436},{"nctId":"NCT06047444","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-10-12","conditions":"Chronic Migraine","enrollment":759},{"nctId":"NCT06183931","phase":"PHASE3","title":"Study of ALXN2220 Versus Placebo in Adults With ATTR-CM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-11","conditions":"Transthyretin Amyloid Cardiomyopathy","enrollment":1181},{"nctId":"NCT04157335","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-11-25","conditions":"Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis","enrollment":295},{"nctId":"NCT04903002","phase":"PHASE2, PHASE3","title":"Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial University of Newfoundland","startDate":"2022-04-01","conditions":"Chronic Pain","enrollment":336},{"nctId":"NCT06965413","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-05","conditions":"Obesity, Overweight, Overweight With One Weight Related Comorbidity","enrollment":285},{"nctId":"NCT07231289","phase":"NA","title":"Effect of Soundscapes on Emotional Distress in Fibromyalgia: a 4×4 Crossover Trial","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2025-11-24","conditions":"Fibromyalgia Syndrome","enrollment":72},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT04732117","phase":"PHASE3","title":"Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-21","conditions":"Non-radiographic Axial Spondyloarthritis","enrollment":137},{"nctId":"NCT06301477","phase":"NA","title":"PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Eastern Ontario","startDate":"2024-12-01","conditions":"Inflammatory Bowel Diseases, Crohn Disease","enrollment":45},{"nctId":"NCT04480840","phase":"PHASE2","title":"Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)","status":"COMPLETED","sponsor":"Pliant Therapeutics, Inc.","startDate":"2020-07-27","conditions":"Primary Sclerosing Cholangitis","enrollment":121},{"nctId":"NCT06373146","phase":"PHASE2","title":"A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Obesity","enrollment":392},{"nctId":"NCT07336992","phase":"PHASE3","title":"Efficacy of Prophylactic Levetiracetam for Improving Functional Outcome in the Acute Phase of Intracerebral Haemorrhage: a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-02","conditions":"Spontaneous Intracerebral Hemorrhage","enrollment":580},{"nctId":"NCT05598112","phase":"EARLY_PHASE1","title":"Effect of Gut Microbiome Intervention on Aging Via Oral FMT","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2023-04-24","conditions":"Aging, Frailty","enrollment":210},{"nctId":"NCT04939597","phase":"PHASE3","title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-05-10","conditions":"Central Nervous System Carcinoma","enrollment":192},{"nctId":"NCT06256991","phase":"PHASE4","title":"Potassium Correction for RAAS Optimization in Chronic Kidney Disease","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-04-01","conditions":"Chronic Kidney Diseases, Hyperkalemia, Hypertension","enrollment":44},{"nctId":"NCT07265180","phase":"NA","title":"Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2025-09-08","conditions":"Schizophrenia Spectrum Disorders (SSD)","enrollment":120},{"nctId":"NCT05194397","phase":"PHASE2","title":"Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-02-23","conditions":"Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia","enrollment":80},{"nctId":"NCT02299440","phase":"PHASE3","title":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2015-04","conditions":"Suicidal Ideation","enrollment":156},{"nctId":"NCT06108219","phase":"PHASE2","title":"A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2023-10-25","conditions":"Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)","enrollment":175},{"nctId":"NCT07037134","phase":"NA","title":"Impact of Auditory Environments on Pain in Fibromyalgia: a 4×4 Crossover Trial","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2025-08-04","conditions":"Fibromyalgia Syndrome","enrollment":88},{"nctId":"NCT05669014","phase":"PHASE2","title":"A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-12-04","conditions":"Idiopathic Inflammatory Myositis","enrollment":12},{"nctId":"NCT06693674","phase":"PHASE3","title":"Effect of Sacubitril-Valsartan on Cardiac Structure and Function","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-03","conditions":"Congenital Heart Disease","enrollment":45},{"nctId":"NCT06873945","phase":"PHASE3","title":"A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-04-01","conditions":"Alopecia Areata","enrollment":550},{"nctId":"NCT05673993","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2023-04-06","conditions":"Primary Sjogren's Syndrome","enrollment":381},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT05306873","phase":"PHASE2","title":"Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-30","conditions":"Systemic Lupus Erythematosus","enrollment":12},{"nctId":"NCT04968184","phase":"PHASE3","title":"Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)","status":"TERMINATED","sponsor":"KBP Biosciences","startDate":"2021-11-05","conditions":"Chronic Kidney Diseases","enrollment":652},{"nctId":"NCT06675500","phase":"PHASE3","title":"Evaluation of the Role of Magnesium in Prevention of AF Post Cardiac Surgery","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-01","conditions":"Atrial Fibrillation (AF), Magnesium Sulfate, Post Cardiac Surgery Patients","enrollment":130},{"nctId":"NCT06506136","phase":"PHASE1, PHASE2","title":"Evaluation of Fluoxetine for Refractory Constipation With Somatic Symptom Disorder Features","status":"NOT_YET_RECRUITING","sponsor":"Zhifeng Zhao, PhD","startDate":"2025-09-01","conditions":"Refractory Constipation, Somatic Symptom Disorder (DSM-5), Functional Constipation (FC)","enrollment":194},{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT04007393","phase":"PHASE2","title":"SMART Use of Medication for the Treatment of Adolescent Severe Obesity","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2019-11-21","conditions":"Adolescent Obesity","enrollment":150},{"nctId":"NCT05824871","phase":"PHASE3","title":"A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients","status":"RECRUITING","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","startDate":"2022-09-02","conditions":"Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)","enrollment":450},{"nctId":"NCT04640077","phase":"PHASE2","title":"A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-23","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":95},{"nctId":"NCT02935686","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-03-31","conditions":"Healthy","enrollment":155},{"nctId":"NCT02788045","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-07-08","conditions":"Healthy","enrollment":201},{"nctId":"NCT05773794","phase":"NA","title":"Scavenging of Reactive Carbonyl Species by Dietary Flavonoids in Humans","status":"COMPLETED","sponsor":"North Carolina Agriculture & Technical State University","startDate":"2023-02-06","conditions":"Human Health, Reactive Carbonyl Species, Polyphenols","enrollment":48},{"nctId":"NCT05737160","phase":"PHASE3","title":"Study of Telitacicept in Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2023-03-28","conditions":"Myasthenia Gravis, Generalized","enrollment":114},{"nctId":"NCT06411899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-05-15","conditions":"Hidradenitis Suppurativa","enrollment":422},{"nctId":"NCT06411379","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-05-14","conditions":"Hidradenitis Suppurativa","enrollment":418},{"nctId":"NCT02975349","phase":"PHASE2","title":"A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-03-07","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":267},{"nctId":"NCT05879406","phase":"NA","title":"A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne","status":"COMPLETED","sponsor":"Ablon Skin Institute Research Center","startDate":"2023-05-31","conditions":"Non-Cystic Acne","enrollment":40},{"nctId":"NCT06327321","phase":"PHASE2","title":"Vitiligo Treatment by Targeting TYK2 Mediated Responses","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-05-05","conditions":"Vitiligo, Generalized","enrollment":128},{"nctId":"NCT06881628","phase":"PHASE4","title":"Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-02","conditions":"Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding, Cirrhosis","enrollment":194},{"nctId":"NCT05325645","phase":"PHASE3","title":"Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2022-07-21","conditions":"Acute Schizophrenia","enrollment":450},{"nctId":"NCT03941132","phase":"PHASE2, PHASE3","title":"Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2021-01-04","conditions":"Type 1 Diabetes Mellitus","enrollment":66},{"nctId":"NCT04073498","phase":"PHASE1, PHASE2","title":"The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)","status":"COMPLETED","sponsor":"ApcinteX Ltd","startDate":"2019-08-14","conditions":"Hemophilia a, Hemophilia B","enrollment":39},{"nctId":"NCT06737042","phase":"PHASE2","title":"Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants","status":"NOT_YET_RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-02-12","conditions":"Obesity and Overweight","enrollment":285},{"nctId":"NCT02919306","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-09","conditions":"Human Immunodeficiency Virus","enrollment":27},{"nctId":"NCT02315703","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2014-12-22","conditions":"Healthy","enrollment":393},{"nctId":"NCT02685020","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-03-28","conditions":"Healthy","enrollment":36},{"nctId":"NCT04426968","phase":"PHASE2","title":"A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2021-06-18","conditions":"Hepatitis B, Chronic","enrollment":96},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":"HIV Infections","enrollment":1512},{"nctId":"NCT03580356","phase":"PHASE3","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-20","conditions":"Chronic Spontaneous Urticaria","enrollment":1078},{"nctId":"NCT04764448","phase":"PHASE2","title":"A Study of Belcesiran in Patients With AATLD","status":"TERMINATED","sponsor":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","startDate":"2021-02-12","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":16},{"nctId":"NCT04944784","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"TERMINATED","sponsor":"Cytokinetics","startDate":"2021-08-16","conditions":"Amyotrophic Lateral Sclerosis","enrollment":489},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT03747939","phase":"PHASE4","title":"Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-12-31","conditions":"Arthritis, Psoriatic","enrollment":310},{"nctId":"NCT04877457","phase":"PHASE4","title":"Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.","status":"TERMINATED","sponsor":"Yale University","startDate":"2022-02-15","conditions":"Radiologically Isolated Syndrome, Multiple Sclerosis","enrollment":3},{"nctId":"NCT03016013","phase":"PHASE3","title":"A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2017-03-29","conditions":"Moderate and Severe RheumatoId Arthritis","enrollment":479},{"nctId":"NCT02771860","phase":"PHASE2","title":"RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-03","conditions":"Hand Osteoarthritis","enrollment":100},{"nctId":"NCT06504420","phase":"PHASE2","title":"The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-15","conditions":"Primary Antiphospholipid Syndrome","enrollment":70},{"nctId":"NCT04543942","phase":"NA","title":"Sex Differences in Risk for Alcohol Abuse","status":"COMPLETED","sponsor":"Mark Fillmore","startDate":"2019-11-01","conditions":"Alcohol Abuse","enrollment":28},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT03201848","phase":"PHASE4","title":"The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qidong Gaitianli Medicines Co., Ltd","startDate":"2017-11-16","conditions":"Immune Thrombocytopenia","enrollment":216},{"nctId":"NCT06285045","phase":"NA","title":"Study on Roujin Formula in the Treatment of Fibromyalgia Syndrome With Blood Deficiency and Liver Depression","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2018-10-01","conditions":"Fibromyalgia Syndrome","enrollment":48},{"nctId":"NCT03653091","phase":"NA","title":"Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"Fractyl Health Inc.","startDate":"2018-09-28","conditions":"Type 2 Diabetes","enrollment":9},{"nctId":"NCT03845075","phase":"PHASE2","title":"48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)","status":"COMPLETED","sponsor":"Saniona","startDate":"2019-02-25","conditions":"Hypothalamic Injury-induced Obesity (HIO)","enrollment":21},{"nctId":"NCT05768334","phase":"PHASE3","title":"Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-01","conditions":"NAFLD","enrollment":116},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT04535986","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2020-09-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":763},{"nctId":"NCT02471144","phase":"PHASE3","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-29","conditions":"Chronic Severe Plaque-type Psoriasis","enrollment":162},{"nctId":"NCT04727528","phase":"PHASE3","title":"Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-22","conditions":"Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease","enrollment":39},{"nctId":"NCT03905525","phase":"PHASE2","title":"Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-10-01","conditions":"Sjögren Syndrome","enrollment":273},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT03580369","phase":"PHASE3","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-17","conditions":"Chronic Spontaneous Urticaria","enrollment":1072},{"nctId":"NCT03978520","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-07-25","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":341},{"nctId":"NCT01730547","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cells for Multiple Sclerosis","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2013-02","conditions":"Multiple Sclerosis","enrollment":2},{"nctId":"NCT04178967","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-10-29","conditions":"Atopic Dermatitis","enrollment":445},{"nctId":"NCT02702180","phase":"PHASE2","title":"Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2016-03-21","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":139},{"nctId":"NCT03272347","phase":"PHASE2","title":"Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-27","conditions":"HIV-1 Infection","enrollment":123},{"nctId":"NCT05744752","phase":"NA","title":"Effects of Allium Sativum and Moringa Oleifera Extract on Dental Enamel","status":"UNKNOWN","sponsor":"Arslan Saleem","startDate":"2022-12-19","conditions":"Lead Poisoning","enrollment":90},{"nctId":"NCT04957550","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-08-30","conditions":"Psoriatic Arthritis","enrollment":444}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo - weeks 24 - 48","genericName":"Placebo - weeks 24 - 48","companyName":"University of Alabama at Birmingham","companyId":"university-of-alabama-at-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo was used as a control intervention in a Phase III study to evaluate the effectiveness and safety of Dysport (Botulinum toxin type A) for the prevention of chronic migraine in adults. This study, conducted by Ipsen, was registered on ClinicalTrials.gov as NCT06047444.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}